Harnessing the Immune System to Fight Multiple Myeloma

Harnessing the Immune System to Fight Multiple Myeloma

Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical behavior, prognosis, and response to treatment. With the advent of novel therapies, many patients achieve long-lasting remissions, but some experience aggressive and treatment refractory relapses. So...

Full description

Bibliographic Details
Main Authors:	Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen, Torben Barington, Niels Abildgaard
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Cancers
Subjects:	multiple myeloma immunotherapy immune modulation allogeneic stem cell transplantation cancer vaccination adoptive cell transfer
Online Access:	https://www.mdpi.com/2072-6694/13/18/4546

Similar Items

Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
by: Alberto Mussetti, et al.
Published: (2020-10-01)

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
by: Ehsan Malek, et al.
Published: (2017-12-01)

The Role of Immunotherapy in Multiple Myeloma
by: Mehmet Kocoglu, et al.
Published: (2016-01-01)

Role of Stem Cell Transplantation in Multiple Myeloma
by: Srinivas Devarakonda, et al.
Published: (2021-02-01)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
by: Gösta Gahrton, et al.
Published: (2020-07-01)

Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect
by: Nico Gagelmann, et al.
Published: (2021-04-01)

Role and Modulation of NK Cells in Multiple Myeloma
by: Marie Thérèse Rubio, et al.
Published: (2021-04-01)

High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells
by: Francesca Garofano, et al.
Published: (2020-05-01)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
by: Estefanía García-Guerrero, et al.
Published: (2020-06-01)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
by: Simone A. Minnie, et al.
Published: (2021-03-01)

Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01)

Adoptive transfer of tumor specific T cells from allogeneic donors is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy
by: Eliza P. Kwiatkowska-Borowczyk, et al.
Published: (2014-03-01)

Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019-06-01)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant? (Running Title: The Role of Salvage alloSCT in MM)
by: Hyunkyung Park, et al.
Published: (2020-07-01)

Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families
by: S. Yado, et al.
Published: (2019-11-01)

Antigen-specific CD8+ memory stem T cells generated from human peripheral blood effectively eradicate allogeneic targets in mice
by: Liping Guan, et al.
Published: (2018-12-01)

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
by: Leona Yamamoto, et al.
Published: (2021-01-01)

Clinical applications of gamma delta T cells with multivalent immunity
by: Drew C Deniger, et al.
Published: (2014-12-01)

Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?
by: Shengli Xu, et al.
Published: (2020-04-01)

Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
by: Faroogh Marofi, et al.
Published: (2021-03-01)

Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
by: Ying Qian, et al.
Published: (2021-05-01)

Present and future of allogeneic natural killer cell therapy
by: Okjae eLim, et al.
Published: (2015-06-01)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
by: Manh-Cuong Vo, et al.
Published: (2018-08-01)

Actors on the Scene: Immune Cells in the Myeloma Niche
by: Patrizia Leone, et al.
Published: (2020-10-01)

Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
by: Ken Maes, et al.
Published: (2019-07-01)

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
by: Niels W. C. J. van de Donk, et al.
Published: (2020-10-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

Cellular immunotherapy in multiple myeloma
by: Manh-Cuong Vo, et al.
Published: (2019-09-01)

Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma
by: Baptiste Lamarthée, et al.
Published: (2018-07-01)

Key Role of the CD56<sup>low</sup>CD16<sup>low</sup> Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
by: Elisabetta Vulpis, et al.
Published: (2018-11-01)

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
by: Kharfan-Dabaja Mohamed A, et al.
Published: (2013-01-01)

Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
by: Weiqing Jing, et al.
Published: (2017-06-01)

Improving the safety of cell therapy with the TK-suicide gene
by: Raffaella eGreco, et al.
Published: (2015-05-01)

Novel Experimental Drugs for Treatment of Multiple Myeloma
by: Offidani M, et al.
Published: (2021-03-01)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)

Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients
by: Femke A. I. Ehlers, et al.
Published: (2021-05-01)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
by: Kenneth J. Caldwell, et al.
Published: (2021-01-01)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
by: Renée Poels, et al.
Published: (2021-01-01)

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
by: Marita Westhrin, et al.
Published: (2018-06-01)

Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells
by: Valentina Bonanni, et al.
Published: (2019-11-01)